Subscribe To
Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting

One clinical poster detailing initial overall survival and immunological biomarker data from the ongoing, randomized, open-label phase 2 clinical trial of CAN-2409 plus standard of care chemoradiation in pancreatic cancer Two preclinical posters characterizing new developments from the enLIGHTEN™ Discovery Platform NEEDHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Nasdaq: CADL), a […] The post Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentati...
Read More
Posted: Sep 27 2023, 13:40
Author Name: forextv
Views: 090759